Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics reported a net loss of $9.91 million for Q2 2026 and $18.94 million for the first half of 2026. This compares to net losses of $10.56 million and net income of $45.98 million for the respective periods in 2025, which included a $70.0 million upfront payment from the Servier Agreement. The company expects its current cash, cash equivalents, and investments to fund operations for at least the next 12 months and continues to evaluate strategic alternatives for its product candidates and seek additional funding.

Black Diamond Therapeutics reported positive Phase 2 results for silevertinib in frontline patients with non-classical EGFRm NSCLC, highlighting no de novo brain metastases and an 86% CNS objective response rate in patients with baseline brain metastases. The company anticipates FDA feedback on a pivotal development path for silevertinib in Q4 2026. Financially, Black Diamond ended Q2 2026 with $110.5 million in cash, cash equivalents, and investments, sufficient to fund operations into the second half of 2028, and reported a net loss of $9.9 million for the quarter.

Black Diamond Therapeutics announced that its Chief Executive Officer, Mark Velleca, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 3, 2026, in New York, NY. The company will also host one-on-one meetings with investors on the same day. A webcast of the presentation will be available on the company's website, with a replay archived for 90 days.

Black Diamond Therapeutics announced positive Phase 2 trial results for silevertinib in frontline non-small cell lung cancer (NSCLC) patients with EGFR non-classical mutations. The trial showed a preliminary median Progression-free Survival (mPFS) of 15.2 months and an Objective Response Rate (ORR) of 60%. Silevertinib also demonstrated robust CNS activity with an 86% CNS ORR and prevented de novo brain metastases. These encouraging data will be presented at the 2026 ASCO Annual Meeting, and the company plans to discuss pivotal development with the FDA.

Black Diamond Therapeutics, a clinical-stage oncology company, announced it will host a webcast for investors on Thursday, May 21, 2026, at 5:30 p.m. ET. The webcast will present updated results from its ongoing Phase 2 trial of silevertinib in frontline patients with EGFR mutated non-small cell lung cancer. Silevertinib is a brain-penetrant fourth-generation EGFR MasterKey inhibitor designed to target families of oncogenic mutations.

Black Diamond Therapeutics reported a net loss of $9.0 million for Q1 2026, compared to a net income of $56.5 million in Q1 2025, with cash, cash equivalents, and investments of $118.3 million as of March 31, 2026, expected to fund operations into 2H 2028. The company announced an oral presentation of silevertinib Phase 2 data in frontline EGFRm NSCLC at the 2026 ASCO Annual Meeting on May 30, 2026. Additionally, the first patient was dosed in the randomized Phase 2 trial of silevertinib in newly diagnosed EGFRvIII+ GBM patients in May 2026.

Black Diamond Therapeutics reported a net loss of $9.04 million for the first quarter of 2026, a significant decline from a net income of $56.54 million in the same period last year. This shift is primarily due to the absence of license revenue in Q1 2026, compared to $70.0 million received in Q1 2025 from the Servier Agreement. The company's cash and cash equivalents stood at $30.07 million, and it expects its current cash to fund operations for at least the next 12 months.

Black Diamond Therapeutics reported a net loss of $9.0 million for the first quarter of 2026, a significant shift from the net income of $56.5 million in Q1 2025. The company ended the quarter with $118.3 million in cash, cash equivalents, and investments, which is projected to fund operations into the second half of 2028. Key corporate updates include an upcoming oral presentation of silevertinib Phase 2 data at the 2026 ASCO Annual Meeting and the dosing of the first patient in a Phase 2 trial for newly diagnosed EGFRvIII+ GBM.

Black Diamond Therapeutics, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 26, 2026. Stockholders will vote on the election of two Class III director nominees, the ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026, and two non-binding advisory votes regarding executive compensation and its frequency. The board recommends voting for all proposals and for an annual frequency for executive compensation votes.

Black Diamond Therapeutics announced multiple presentations for its MasterKey therapy, silevertinib, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentations will include an oral session on Phase 2 data for silevertinib in treatment-naïve NSCLC patients with non-classical EGFR mutations. Additionally, two poster sessions will cover Phase 2 data in previously treated NSCLC and a trial-in-progress for newly diagnosed EGFRvIII-positive glioblastoma (GBM).